TULIP 1 - highlights from the ACR meeting
Update: 2019-12-10
Description
TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
